Experimental combo for tough cancers shows early promise, but trial halted
NCT ID NCT02298153
First seen Apr 30, 2026 · Last updated Jun 20, 2026 · Updated 9 times
Summary
This early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Harvard-Mass General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Pinnacle Oncology Hematology
Scottsdale, Arizona, 85258, United States
-
University of Washington
Seattle, Washington, 98109, United States
-
Yale University
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (immunotherapy) and epacadostat (oral drug that boosts immune response)
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung and bladder cancers that have stopped responding to standard chemotherapy.
What could go wrong
This was a very early (Phase 1) safety study with only 29 participants, and it was terminated early, so we don't know if the combination works or is safe long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.